Skip to main content

For informational and research purposes only.

Medical DisclaimerTerms of Use

Resistant Starch: The Definitive Guide

Why product mass differs from resistant-starch mass, how processing changes the ingredient, and where metabolic and bowel claims exceed the trials.

Resistant starch at a glance

Starch type, product mass and resistant fraction define different interventions.

Resistant starch

RS2 · RS3 · food matrices

Product mass ≠ resistant-starch mass

Keep three quantities separate

  1. 1

    Product

    Total powder or food mass.

  2. 2

    RS fraction

    Measured resistant starch within it.

  3. 3

    Outcome

    Meal, long-term or microbiome result.

Category

StarchResists digestion

Destination

ColonVariable fermentation

Metabolic evidence

Mixed outcomes

Main limit

Individual response

Resistant starch is a family defined by resistance to small-intestinal digestion. Type, source, processing and measured resistant fraction are part of the intervention.
Published by DoserlyUpdated Next scheduled review: April 202713 min readHow this guide was made
In this guide

What is resistant starch?

Resistant starch is starch and starch-degradation material that escapes digestion in the small intestine. The fraction reaching the colon can be fermented by microbes, so it overlaps functionally with dietary fibre. Resistance can come from physical enclosure in a food, an ungelatinized granular structure, retrogradation after cooking and cooling, chemical modification or a starch-lipid complex. [1], [2]

The common numbered forms are descriptive categories. RS1 is physically inaccessible within intact structures; RS2 is granular starch in sources such as raw potato, green banana or high-amylose maize; RS3 is retrograded starch formed after gelatinized starch cools; RS4 is chemically modified; and RS5 is complexed with lipid. A trial of HAM-RS2 does not prove that cooked-and-cooled rice, raw potato starch and an RS4 bakery ingredient have the same dose or effect. [2]

Mass and identity

A powder amount is not automatically its RS amount

67 g productHi-Maize 260 in Bodinham
60% resistantMeasured fraction in that product
40 g RS2Daily resistant-starch exposure

Do not copy the active fraction onto every scoop or other product.

Bodinham’s 67 g Hi-Maize product contained 40 g RS2. The product mass, resistant fraction and daily RS exposure must remain separate. Sources: Bodinham diabetes trial.

Typical Resistant Starch Protocols

These are descriptive study schedules, not interchangeable recommendations. Product mass and resistant-starch mass are reported separately where the source allows. [4], [5], [6], [7]
Study and populationExact productAmount each administrationFrequencyDaily total and durationMain interpretation
Bodinham 2014 · 17 adults with well-controlled type 2 diabetesHi-Maize 260, 60% HAM-RS233.5 g product per sachet; 20 g RS2Twice daily67 g product providing 40 g RS2/day for 12 weeksMeal glucose improved; HbA1c and clamp insulin sensitivity did not
Peterson 2018 · 68 adults with prediabetes; 59 analyzedHi-Maize 260 HAM-RS2 in yogurt and packetsNot reportedDaily schedule not reported45 g RS2/day for 12 weeksNo meaningful glycemic or broad cardiometabolic improvement
Venkataraman 2016 · 20 healthy young adultsRaw unmodified potato starch, about 50% RS224 g product; about 12 g RS2 after rampTwice daily after a 3-day ramp48 g product providing about 24 g RS2/day for 7 maintenance daysFecal butyrate response varied substantially
Luk-In 2024 · 98 Thai adults with chronic constipation; 87 completedHaruna Plus mixed-source RS39 gOnce daily9 g/day for 12 weeksNo significant between-group difference in stool frequency, consistency or constipation score

The Bodinham paper states that participants used two daily sachets, so its per-administration product and RS2 amounts can be calculated directly from that explicit schedule. Peterson reports 45 g/day delivered through yogurts and packets but does not disclose a defensible equal split; “not reported” is more accurate than dividing it. Venkataraman ramped product mass from 12 g on day one to 24 g on day two and 48 g on day three before seven maintenance days. [4], [5], [6]

Product versus active fraction
A potato or maize starch powder can contain digestible starch as well as RS. Record both values when the source provides them.
RS type
RS2 and RS3 are created by different structures. A quantity from one cannot define the other.
Comparator
Bodinham and Peterson used rapidly digestible starch comparators; Luk-In used a soy-protein/isomalt placebo. Comparator effects can influence the difference.

What is resistant starch commonly used for?

Post-meal glucose and long-term glycemic control

Bodinham’s small crossover study found lower postprandial glucose after 12 weeks of HAM-RS2 and a larger post-meal GLP-1 excursion. Those signals did not extend to fasting glucose, insulin, HbA1c, hepatic insulin sensitivity or peripheral clamp insulin sensitivity. Fasting triglycerides and soleus intramuscular triglycerides were higher after HAM-RS2, an unfavorable signal with uncertain clinical meaning. [4]

Peterson’s larger parallel trial is the counterweight. Relative to amylopectin, 45 g/day HAM-RS2 reduced HbA1c by only 0.1 percentage point, which the authors called clinically insignificant, and did not improve insulin secretion, insulin sensitivity, disposition index, meal glucose or insulin areas, ectopic fat, energy expenditure or most cardiovascular measures. Heart rate and TNF-alpha fell, but baseline TNF-alpha was higher in the RS2 group. Ingredion supplied both products, and two authors reported prior company research funding or product gifts; sponsors had no role in the trial. [5]

Fermentation and butyrate

Venkataraman observed a cohort increase in fecal butyrate from 8 to 12 mmol/kg after raw potato starch, but response groups diverged. Eleven participants increased from about 9 to 15 mmol/kg, three started and remained high, and six remained at or below 8 mmol/kg. Changes in resistant-starch degraders helped explain some variation. Fecal butyrate is still an intermediate outcome influenced by production, absorption and transit; the study did not test symptom relief or disease prevention. [6]

Constipation

Luk-In’s mixed-source RS3 product produced favorable within-group changes and microbiome shifts. Yet placebo participants also improved, and direct between-group differences in stool frequency, Bristol stool score and modified constipation score were not significant. The reported 80% reaching at least four bowel movements per week describes the active group, not a significant placebo-adjusted effect. The formulation was an autoclaved-and-cooled blend of ginkgo nut, spinach, corn and brown rice, so it cannot validate home-cooled starch at the same weight. [7]

Twenty-person mechanistic study

The same potato starch produced three butyrate patterns

11 enhancedFecal butyrate rose during RS2
3 already highHigh before and during RS2
6 remained lowNo clear butyrate response

These are fecal biomarker clusters, not symptom responder rates.

The same short potato-starch exposure produced enhanced, already-high and persistently-low fecal butyrate patterns. These are biomarker clusters, not symptom response rates. Sources: Venkataraman microbiome study.

How do you read the form and label?

Look for the starch source, RS type, product grams per serving, measured resistant-starch grams and testing method. “High amylose” does not tell you the exact resistant fraction after processing. Raw potato starch loses much of its granular resistance when heated with moisture; a cooked finished food cannot inherit the raw-powder value. RS3 depends on gelatinization, cooling, storage and reheating conditions. [2], [8]

Cooking and cooling can increase retrograded starch, but the amount is food- and process-specific. It does not erase digestible carbohydrate, energy or glycemic impact. Home preparation without laboratory measurement should be described as a processing strategy, not a known gram dose.

In the United States, FDA guidance recognizes certain resistant starches for dietary-fibre declaration based on evidence for physiological effects. That is a labelling determination, not approval to treat diabetes or constipation. Canada treats naturally occurring RS1 and conventional RS3 as dietary fibre and evaluates some manufactured RS sources within its novel-fibre evidence framework. [3], [8]

How should resistant starch be stored?

Keep powders sealed, dry and away from humidity. Follow product directions and avoid heating raw RS2 products when the intended property depends on intact granules. Prepared starchy foods require ordinary food-safety refrigeration and reheating practices; creating RS3 does not make cooked rice or potatoes safe to leave at room temperature. A multi-ingredient fibre blend may have different storage requirements from plain starch.

What does the human evidence show?

Conceptual comparison of laboratory, animal and human research records.
Digestibility testing, fecal butyrate, meal glucose and long-term clinical markers answer different questions. This is a conceptual illustration, not resistant-starch outcome data.
QuestionBest direct evidence hereAnswerMain limit
Does HAM-RS2 improve long-term diabetes control?17-person crossover trialNo HbA1c or clamp-sensitivity benefitSmall sample; post-meal signal only
Does 45 g/day RS2 improve prediabetes broadly?68-person parallel RCTNo meaningful glycemic or broad cardiometabolic benefit59 analyzed; supplied product and prior company ties
Does potato RS2 raise butyrate in everyone?20-person mechanistic studyNo; 6 stayed lowShort uncontrolled exposure; fecal biomarker
Does 9 g/day mixed RS3 outperform placebo for constipation?98-person randomized trialNo significant difference on main stool indexesWithin-group improvement and favorable trends

These studies use different populations, products and outcomes. A positive meal test, a lower inflammatory marker, more fecal butyrate and easier stooling are not interchangeable endpoints. The most useful conclusion is that resistant starch can alter physiology, while clinically important effects remain product- and context-dependent. [4], [5], [6], [7]

What are the risks and interactions?

Gas, bloating, cramps, altered stool frequency and loose stool are expected fermentation-related effects. Rapid increases can be difficult to tolerate. A new symptom is not proof of beneficial “feeding” or detoxification. Severe or persistent abdominal pain, vomiting, marked distension, blood in stool, fever, dehydration or signs of obstruction require assessment.

Resistant starch can change post-meal glucose in some settings. People using insulin or glucose-lowering medicine should avoid assuming a predictable effect from one product or cooled food and should discuss meaningful dietary changes with their clinician. Suspected obstruction, severe motility disorders, active inflammatory disease or recent gastrointestinal surgery also call for clinical review. Fibre can alter transit; follow medicine-specific instructions rather than applying the two-hour spacing used in one RS3 study to all medicines.

What is the legal and regulatory status?

In the United States, resistant-starch products may be conventional foods or dietary supplements. FDA dietary-fibre recognition applies to defined ingredients and physiological evidence; it is not disease-treatment approval. In Canada, conventional RS1 and RS3 and accepted manufactured fibres fall under product- and evidence-specific food rules. A powder sold as a natural health product can follow a different classification pathway. [3], [8]

What happens when you stop?

Resistant starch does not cause drug-like withdrawal. Fermentation, fecal butyrate and stool pattern may return toward baseline when the substrate is removed. A meal response may change immediately with the food matrix, while microbial measurements can lag. No validated taper exists; persistent symptoms after stopping suggest another dietary or medical factor.

What should you monitor?

Record product grams, stated resistant-starch grams, type, preparation and meal context. Choose one primary outcome: stool frequency, Bristol stool form, bloating score or clinician-guided glucose measure. Note a baseline and concurrent fibre, probiotic, laxative and medication changes. Review at the study-relevant window, from days for fermentation to 12 weeks for the metabolic trials, without overlooking earlier intolerance.

What does community experience add?

Public reports can surface gas, preparation confusion and the difference between powder scoops and cooled foods. They rarely measure the resistant fraction or control diet, medicines and baseline microbiome. No systematic current community sample was assembled, so no consensus percentage, titration schedule or responder rate is reported.

How do resistant-starch forms compare?

OptionIdentityEvidence boundary
HAM-RS2High-amylose maize productMetabolic trials at 40–45 g RS2/day; mixed and mostly negative long-term outcomes
Raw potato RS2Ungelatinized potato granulesShort microbiome study used 48 g product, about 24 g RS2/day
Mixed-source RS3Autoclaved-and-cooled commercial blendOne 9 g/day constipation trial without significant main between-group differences
Cooked-and-cooled foodFood-specific retrograded starchActual RS depends on food, processing, storage and reheating
PsylliumViscous gel-forming fibreDifferent mechanism, medication-spacing concerns and bowel evidence

Common questions

Is resistant starch a dietary fibre?

It functions as fibre because it escapes small-intestinal digestion. Labelling treatment still depends on jurisdiction, type and evidence. [3], [8]

Is raw potato starch all resistant starch?

No. Venkataraman’s product was about 50% RS2 by weight. Product mass was roughly twice the estimated RS amount. [6]

Does cooking and cooling increase resistant starch?

It can create RS3 through retrogradation, but the amount depends on the food and process. It does not remove all digestible starch.

Does resistant starch lower blood glucose?

Bodinham found a post-meal signal without better HbA1c or clamp sensitivity. Peterson found no meaningful broad glycemic improvement. [4], [5]

Does it help constipation?

The 2024 RS3 trial improved from baseline, but direct comparisons with placebo on the main stool indexes were not significant. [7]

Does everyone produce more butyrate?

No. Six of 20 participants in one short potato-starch study remained in the low-response group. [6]

Is more resistant starch better?

No dose-response across forms is established. Larger fermentable loads can worsen tolerance, and trial quantities cannot be transferred across products.

Glossary

Plain explanations of resistant-starch and outcome terms.

RS2
Resistant starch protected by its native granular structure, as in raw potato or high-amylose maize.
RS3
Retrograded starch formed when gelatinized starch molecules reassociate during cooling.
Gelatinization
Heat-and-moisture disruption of starch granules that usually increases digestibility.
Retrogradation
Reassociation of cooked starch chains during cooling, which can increase digestion resistance.
Butyrate
A short-chain fatty acid made by microbial fermentation; fecal concentration reflects several processes.
Euglycemic clamp
A controlled research method for measuring insulin sensitivity.

How this guide was researched

Primary full reports supplied the exact product, resistant fraction, schedule, comparator and outcome boundaries for HAM-RS2, potato RS2 and mixed RS3. Negative glycemic results, higher triglyceride signals, Peterson’s participant flow and company relationships, Venkataraman’s low-response group and Luk-In’s nonsignificant between-group stool results remain explicit. Official US and Canadian documents supplied fibre-labelling distinctions. Community claims were not quantified.

Research record · checked October 9, 2026

Fresh reads: full primary reports for Bodinham 2014, Peterson 2018, Venkataraman 2016 and Luk-In 2024 were checked.

Protocol verification: product mass and estimated RS mass are separated; Peterson’s unreported administration split was not invented.

Negative evidence: null HbA1c and insulin-sensitivity findings, triglyceride signals, microbiome nonresponders and nonsignificant RS3 placebo comparisons remain visible.

Claim boundary: fecal butyrate, microbiome abundance and within-group stool changes were not promoted into clinical efficacy.

Explore the sources

Primary human studies, reviews and official fibre guidance supporting this guide.

Showing 8 sources

  1. 01

    Resistant starch definition in Dietary Reference Intakes ↗

    Reference definition

    Class definition and digestion boundary.

  2. 02

    Resistant starch: promise for improving human health. ↗

    Scientific review

    Types, processing and mechanistic context.

  3. 03

    Scientific evidence on physiological effects of non-digestible carbohydrates ↗

    Official evidence review

    US dietary-fibre labelling context.

  4. 04

    Efficacy of increased resistant starch consumption in human type 2 diabetes. ↗

    Randomized crossover trial

    Exact product fraction, meal signal, null outcomes and triglycerides.

  5. 05

    Effect of 12 wk of resistant starch supplementation on cardiometabolic risk factors in adults with prediabetes: a randomized controlled trial. ↗

    Randomized controlled trial

    Participant flow, broad null outcomes and disclosures.

  6. 06

    Variable human microbiome responses to resistant starch ↗

    Human mechanistic study

    Exact potato-starch schedule and heterogeneous butyrate response.

  7. 07

    Impact of resistant starch type 3 on fecal microbiota and stool frequency in Thai adults with chronic constipation randomized clinical trial. ↗

    Randomized controlled trial

    Product-specific protocol and nonsignificant main between-group comparisons.

  8. 08

    Policy for Labelling and Advertising of Dietary Fibre-Containing Food Products ↗

    Official policy

    Canadian RS types and novel-fibre evidence requirements.

Editorial note

This guide preserves exact product and active-fraction amounts, negative comparator findings, sponsor context and the distinction between biomarkers and clinical outcomes. It was authored in English for translation from the same evidence record.